This hormone plays a major role in controlling appetite, regulating blood sugar, slowing gastric emptying, and signaling the brain that youre satisfied
Side Effects & Safety Considerations The adverse event profile of MOUNJARO (tirzepatide) is predominantly gastrointestinal, aligning with the incretin receptor agonist class, with frequency and severity correlating to dose and titration speed.[3][4] Most common reactions include nausea, diarrhea, vomiting, abdominal pain, constipation, dyspepsia, and decreased appetite.[3][4] These effects are typically mild-to-moderate, peak during dose escalation, and lessen over time on a stable dose.[3] If tolerability is significantly compromised, providers should consider delaying escalation or extending the current dose interval
Mohseni Y, Vazirnia A, Minokadeh A, Amron DM, Coleman WP 3rd
Scotland offers the drug through both primary care and specialist weight management services, with specific criteria set by each health board
While some plans may provide coverage for certain weight-related conditions, eligibility is determined by the insurer